Teva Pharmaceutical (TEVA)
NYSE:TEVA
Want to see TEVA full AI Analyst Report?
Total Valuation
Teva Pharmaceutical has a market cap or net worth of $41.54B. The enterprise value is $55.17B.
Market Cap$41.54B
Enterprise Value$55.17B
Share Statistics
Teva Pharmaceutical has 1,164,638,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,164,638,700
Owned by Insiders0.47%
Owned by Institutions5.29%
Financial Efficiency
Teva Pharmaceutical’s return on equity (ROE) is 0.18 and return on invested capital (ROIC) is 7.41%.
Return on Equity (ROE)0.18
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)7.41%
Return on Capital Employed (ROCE)0.08
Revenue Per Employee466.41K
Profits Per Employee38.32K
Employee Count37,000
Asset Turnover0.42
Inventory Turnover2.62
Valuation Ratios
The current PE Ratio of Teva Pharmaceutical is 23.6. Teva Pharmaceutical’s PEG ratio is -0.14.
PE Ratio23.6
PS Ratio2.08
PB Ratio4.53
Price to Fair Value4.53
Price to FCF31.24
Price to Operating Cash Flow17.05
PEG Ratio-0.14
Income Statement
In the last 12 months, Teva Pharmaceutical had revenue of 17.26B and earned 1.41B in profits. Earnings per share was 1.23.
Revenue17.26B
Gross Profit8.94B
Operating Income2.16B
Pretax Income1.24B
Net Income1.41B
EBITDA3.14B
Earnings Per Share (EPS)1.23
Cash Flow
In the last 12 months, operating cash flow was 1.71B and capital expenditures -542.00M, giving a free cash flow of 1.17B billion.
Operating Cash Flow1.71B
Free Cash Flow1.17B
Free Cash Flow per Share1.01
Dividends & Yields
Teva Pharmaceutical pays an annual dividend of $0.085, resulting in a dividend yield of ―
Dividend Per Share$0.085
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.68
52-Week Price Change106.48%
50-Day Moving Average31.63
200-Day Moving Average25.08
Relative Strength Index (RSI)61.60
Average Volume (3m)6.03M
Important Dates
Teva Pharmaceutical upcoming earnings date is Aug 5, 2026, Before Open (Confirmed).
Last Earnings DateApr 29, 2026
Next Earnings DateAug 5, 2026
Ex-Dividend Date―
Financial Position
Teva Pharmaceutical as a current ratio of 1.04, with Debt / Equity ratio of 205.48%
Current Ratio1.04
Quick Ratio0.80
Debt to Market Cap0.48
Net Debt to EBITDA4.40
Interest Coverage Ratio2.35
Taxes
In the past 12 months, Teva Pharmaceutical has paid -180.00M in taxes.
Income Tax-180.00M
Effective Tax Rate-0.15
Enterprise Valuation
Teva Pharmaceutical EV to EBITDA ratio is 15.82, with an EV/FCF ratio of 43.28.
EV to Sales2.88
EV to EBITDA15.82
EV to Free Cash Flow43.28
EV to Operating Cash Flow30.13
Balance Sheet
Teva Pharmaceutical has $3.74B in cash and marketable securities with $16.91B in debt, giving a net cash position of -$13.17B billion.
Cash & Marketable Securities$3.74B
Total Debt$16.91B
Net Cash-$13.17B
Net Cash Per Share-$11.30
Tangible Book Value Per Share-$10.33
Margins
Gross margin is 51.98%, with operating margin of 12.50%, and net profit margin of 8.17%.
Gross Margin51.98%
Operating Margin12.50%
Pretax Margin7.17%
Net Profit Margin8.17%
EBITDA Margin18.20%
EBIT Margin12.39%
Analyst Forecast
The average price target for Teva Pharmaceutical is $42.38, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$42.38
Price Target Upside30.79% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast5.76%
EPS Growth Forecast―